Syros Pharmaceuticals Inc (LTS:0LC7)
$ 0.2 0 (0%) Market Cap: 5.44 Mil Enterprise Value: 7.39 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 18/100

Q3 2024 Syros Pharmaceuticals Inc Earnings Call Transcript

Oct 31, 2024 / 12:30PM GMT
Release Date Price: $2.53 (+0.80%)
Operator

Good morning, and welcome to the Syros Pharmaceuticals Third Quarter 2024 Financial Results Conference Call. (Operator Instructions) Note that this call is being webcast live on the Investors and Media section of Syros' website at www.syros.com. Please be advised that today's call is being recorded.

At this time, I would like to turn the call over to Karen Hunady, Director of Investor Relations and Corporate Communications at Syros. Please go ahead.

Karen Hunady
Syros Pharmaceuticals Inc - Director of Corporate Communications & Investor Relations

Thank you. This morning, we issued a press release announcing our third quarter 2024 financial results. The full release is available on the Investors & Media section of Syros' website at www.syros.com. We will begin the call with prepared remarks by Conley Chee, our Chief Executive Officer; Dr. David Roth, our Chief Medical Officer; and Jason Haas, our Chief Financial Officer.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot